PTC Therapeutics (NASDAQ: PTCT) reported fourth-quarter results that missed Wall Street expectations on both earnings and revenue, even as management pointed to strong momentum from the recent launch ...

CEO Matthew Klein highlighted 2025 as a year of “many significant successes,” citing the initial global approvals and launch of Sephience for PKU as the main highlight. Klein stated, “The global ...

PTC Therapeutics, Inc. PTCT closed lower on Thursday following the company’s decision to withdraw its New Drug Application for Translarna after receiving feedback from the U.S. Food and Drug ...

In a statement, PTC's chief executive, Matthew Klein, said the company had decided to pull the filing for Translarna (ataluren) as a treatment for nonsense mutation DMD after the FDA said it was ...

PTC Therapeutics Inc (PTCT) reports robust financial performance, exceeding revenue guidance and outlining strategic initiatives for continued growth in 2026.

Detailed price information for Ptc Therapeutics (PTCT-Q) from The Globe and Mail including charting and trades.

Boston, Massachusetts-based PTC Inc. (PTC) provides software solutions and services globally that aid manufacturing companies in designing, operating, and managing products. With a market cap. of $18.

PTC (NASDAQ: PTC) has outperformed the market over the past 10 years by 7.24% on an annualized basis producing an average annual return of 20.37%. Currently, PTC has a market capitalization of $24.39 ...

Investing.com -- PTC Inc (NASDAQ:PTC) stock fell 3.8% on Thursday after Google announced a major upgrade to its Gemini 3 Deep Think AI system, potentially challenging PTC’s position in the engineering ...